ArticleJAMA network open2026
Age at Diagnosis and Clinical and Genetic Profiles Among Adults With Attention-Deficit/Hyperactivity Disorder.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Adult attention-deficit/hyperactivity disorder (ADHD) diagnoses are rising, yet distinctions between those diagnosed in childhood or adolescence vs adulthood remain underexplored. Objectives: To characterize differences in demographic, clinical, and genetic profiles between adults with ADHD diagnosed in childhood or adolescence (youth-diagnosed) vs adulthood (adult-diagnosed), and to compare the profile of each group with that from matched individuals without ADHD. Design, Setting, and Participants: This cross-sectional, multicenter study used data collected in the All of Us Research Program, a nationwide US cohort integrating clinical and genetic data, from June 2017 to September 2023. Analyses were performed between July and December 2025. Participants were adults who self-reported an ADHD diagnosis, dichotomized by age at first diagnosis into youth-diagnosed (0-17 years) and adult-diagnosed (≥18 years) ADHD groups. Each ADHD group was independently matched 1:2 via propensity scores to controls without ADHD on age, sex, race and ethnicity, educational attainment, and income. Main Outcomes and Measures: The primary outcomes were self-reported psychiatric or somatic co-occurring conditions, measures of functional impairment (general health and daily functioning), and ADHD polygenic risk scores. Results: Of 13 527 adults with ADHD, 3853 (28.5%; mean [SD] age, 34.8 [11.5] years; 71.5% female) were youth-diagnosed and 9674 (71.5%; mean [SD] age, 43.8 [14.3] years; 75.3% female) adult-diagnosed. Adult-diagnosed individuals were older and had higher educational attainment (eg, 548 [14.2%] vs 2690 [27.8%] for advanced degree) and annual household income (eg, 364 [9.4%] vs 1407 [14.5%] for $100 001-$150 000). Adjusting for age and sex, adult- versus youth-diagnosed ADHD was associated with lower adjusted probabilities of most psychiatric comorbidities (8 of 9 conditions) with the largest absolute differences for posttraumatic stress disorder (-7.50 [95% CI, -9.25 to -5.88] percentage points [pp]), bipolar disorder (-7.44 [95% CI, -8.99 to -6.00] pp), and personality disorder (-4.78 [95% CI, -5.89 to -3.81] pp). For somatic conditions (6 of 9 categories), the largest absolute differences were for lung conditions (-7.88 [95% CI, -9.73 to -5.79] pp), digestive conditions (-7.27 [95% CI, -9.12 to -5.28] pp), and bone, joint, and muscle conditions (-7.00 [95% CI, -8.78 to -5.20] pp). For impairment in overall health and daily functioning (7 of 9 measures), the largest absolute differences were for physical health (-3.63 [95% CI, -4.83 to -2.44] pp), being bothered by emotional problems in the past 7 days (-2.51 [95% CI, -3.79 to -1.24] pp), and general health (-2.26 [95% CI, -3.40 to -1.18] pp). Compared with their matched controls without ADHD, both ADHD groups showed markedly higher probability differences of comorbid psychiatric (eg, for depression, 39.33 [95% CI, 38.19-40.48] pp for adult-diagnosed ADHD and 36.92 [95% CI, 35.05-38.83] pp for youth-diagnosed ADHD) and somatic (eg, for brain and nervous system conditions, 21.86 [95% CI, 20.64-22.93] pp for adult-diagnosed ADHD and 22.84 [95% CI, 21.05-24.83] pp for youth-diagnosed ADHD) conditions, and functional impairments (eg, for bothered by emotional problems past 7 days, 6.11 [95% CI, 5.45-6.80] pp for adult-diagnosed ADHD and 7.29 [95% CI, 5.99-8.60] pp for youth-diagnosed ADHD). ADHD polygenic risk scores were lower in adult- vs youth-diagnosed groups (Cohen d, -0.17 [95% CI, -0.21 to -0.12]) and higher in youth-diagnosed (Cohen d, 0.21 [95% CI, 0.16-0.26]) and adult-diagnosed (Cohen d, 0.12 [95% CI, 0.09-0.15]) groups compared with controls. Conclusions and Relevance: In this cross-sectional study of adults with ADHD, individuals first diagnosed with ADHD in adulthood showed a milder ADHD-like clinical and genetic profile than those diagnosed in childhood or adolescence, which may contribute to later recognition of the disorder. Nonetheless, adults diagnosed either as youths or adults exhibited profiles characteristic of ADHD relative to matched controls without ADHD, including substantial burden, supporting adult-diagnosed ADHD as a clinically important subgroup warranting recognition and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.